The $65 price level has become a focal point for Boston Scientific investors because it represents the convergence of several important signals. Since June 2026, at least five major Wall Street firms—including Stifel, BTIG, Piper Sandler, and Evercore ISI—have independently set or revised their price targets to exactly $65. This clustering is not accidental. Analysts appear to be anchoring to a valuation framework that applies a forward price-to-earnings (P/E) multiple in the mid-to-high teens to projected 2027 earnings, and $65 is where those models consistently land.
For shareholders who watched BSX plummet from over $100 to the low $40s in less than a year, reclaiming $65 would represent a meaningful recovery—restoring roughly half the value lost during the drawdown—without requiring a return to the growth exuberance that characterized the stock's 2024-2025 rally.
Boston Scientific Corporation is a global medical technology leader headquartered in Marlborough, Massachusetts. Founded in 1979, the company develops and manufactures minimally invasive medical devices across two operating segments: Cardiovascular and MedSurg. Its portfolio spans interventional cardiology, cardiac rhythm management, electrophysiology, left atrial appendage closure (the WATCHMAN platform), endoscopy, urology, and neuromodulation. The company generated $20.07 billion in revenue during fiscal 2025, representing nearly 20% growth, and employs approximately 59,000 people worldwide.
Understanding whether BSX can reach $65 requires first understanding why it fell so far. In February 2026, management guided for 10% to 11% organic sales growth for the full year—a sharp deceleration from the 19.5% delivered in 2025. Investors reacted harshly, but the real damage came in waves. By April, organic growth guidance was trimmed to 6.5% to 8.0%. Then in late May, CEO Michael Mahoney disclosed that WATCHMAN stand-alone procedures were declining and that sequential dollar growth for the overall business would likely be flat from the first quarter through the third quarter.
The WATCHMAN device, a left atrial appendage closure implant that prevents stroke in patients with atrial fibrillation, had been one of Boston Scientific's most important growth engines. Its sudden stall—attributed to physician workflow constraints, capacity issues in operating rooms, and shifting reimbursement dynamics—undermined the market's confidence in the company's near-term trajectory. Compounding the pressure, several analysts downgraded the stock or shifted to the sidelines, and Wolfe Research cut its rating to Peerperform, citing growth concerns.
Despite the gloom, several factors support the case for a recovery toward $65. First, Boston Scientific's broader portfolio remains healthy. First-quarter 2026 revenue of $5.20 billion grew 11.6% year-over-year, and the company beat consensus earnings per share (EPS) estimates. The FARAPULSE pulsed field ablation (PFA) system continues to gain adoption in the electrophysiology market, and clinical data presented at Heart Rhythm 2026 demonstrated strong safety and efficacy across multiple platforms.
Second, management has deployed an unusually aggressive capital-return strategy. In May 2026, the board authorized a $5 billion share repurchase program—equivalent to roughly 7.5% of the company's market capitalization—including a $2 billion accelerated share repurchase. Boston Scientific has not been an active buyer of its own stock since fiscal 2020, making this move a powerful signal that leadership views the shares as undervalued.
Third, the company's investment in MiRus LLC—a $1.5 billion stake for 34% ownership with an option to acquire the MiRus transcatheter aortic valve replacement (TAVR) system for $3 billion—demonstrates a willingness to deploy capital toward future growth platforms that could reinvigorate the product pipeline.
Wall Street remains broadly constructive despite the numerous target reductions. Of the 30 analysts covering BSX, 26 maintain Buy or Outperform ratings, four are at Hold, and two rate the stock a Sell. The average 12-month price target stands at approximately $72 to $81 depending on the data source, with the median near $70. The lowest target is $55 (Wells Fargo, Equal Weight), and the highest remains $118.
Recent adjustments tell a nuanced story. Needham cut its target to $57 from $77 but kept a Buy rating, modeling flat WATCHMAN sales through 2028. TD Cowen maintained Buy at $61. Jefferies reiterated Buy but slashed its target from $100 to $67. These cuts reflect downside risks that have already materialized, and the fact that most firms kept positive ratings suggests that much of the bad news may be priced in.
From a technical analysis perspective, BSX has established a clear support zone near $42.20, which marks the 52-week low and has been tested multiple times during July 2026 without breaking. On the upside, the 50-day moving average near $48 to $50 represents the first significant resistance level. A convincing move above that zone would signal improving momentum and open a path toward the 200-day moving average around $66 to $67—conveniently near the $65 target under discussion.
The psychological importance of $65 cannot be overstated. It sits just below the 200-day moving average, which often acts as a dividing line between bearish and bullish long-term sentiment. Reclaiming this level would also mean the stock had retraced roughly 38.2% of its decline from the September 2025 peak—a Fibonacci level that technicians frequently monitor as an initial recovery benchmark.
The path to $65 is not without significant obstacles. The WATCHMAN slowdown may prove structural rather than temporary if physician workflow constraints persist or if competing technologies erode market share. Additionally, Boston Scientific faces several Class II device recalls in 2026 affecting gastrointestinal valves, CRE balloon devices, and cardiac monitors, which could pressure the MedSurg segment's growth and invite increased regulatory scrutiny.
There is also the risk that analyst price targets themselves continue to drift lower. The consensus target has already fallen from approximately $116 a year ago to around $80 today, and second-quarter earnings due on July 29, 2026 will be a critical test. If management signals further deterioration in WATCHMAN trends or cuts full-year guidance again, targets could compress further—potentially dragging the "achievable" recovery level below $65.
Navigating a volatile stock like Boston Scientific requires timely and data-driven decision-making. Tickeron's AI Daily Buy/Sell Signals offers traders an AI-powered tool that continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and advanced algorithmic analysis. By surfacing real-time trading opportunities, the platform enables traders to track shifting trends, manage active positions, and identify emerging setups without manually scanning the market. For those seeking to stay ahead of fast-moving market dynamics, exploring AI-driven signal technology can add a valuable layer of analytical support to any trading workflow.
A move to $65 for Boston Scientific stock is realistic but conditional. The company retains a diversified, revenue-generating portfolio with multiple growth platforms beyond WATCHMAN, and management's $5 billion buyback demonstrates conviction in the stock's undervaluation. The majority of Wall Street analysts continue to rate BSX a Buy with price targets above $65, and the stock's forward P/E ratio of approximately 12.9 suggests it is no longer priced for perfection.
However, reaching $65 will almost certainly require stabilization in the WATCHMAN franchise, successful execution on the 2026 organic growth guidance of 6.5% to 8.0%, and a broader shift in market sentiment that allows the stock's valuation multiple to expand from its currently depressed levels. The July 29 earnings report represents the next major catalyst. If management can demonstrate that WATCHMAN headwinds are manageable and that the broader portfolio remains on track, the case for a recovery toward $65 strengthens considerably. Without those signals, the stock may remain range-bound between support at $42 and resistance near $50 for longer than bulls would hope.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +2.85% | ||
| ISRG - BSX | 71% Closely correlated | +5.73% | ||
| MMSI - BSX | 56% Loosely correlated | +2.40% | ||
| ALC - BSX | 49% Loosely correlated | -0.93% | ||
| NTRA - BSX | 45% Loosely correlated | -1.51% | ||
| MDT - BSX | 44% Loosely correlated | +1.21% | ||
More | ||||
| Ticker / NAME | Correlation To BSX | 1D Price Change % |
|---|---|---|
| BSX | 100% | +2.85% |
| BSX (2 stocks) | 15% Poorly correlated | +4.29% |
| Medical/Nursing Services (138 stocks) | 1% Poorly correlated | +1.05% |
| Health Services (243 stocks) | 0% Poorly correlated | +0.90% |